scholarly journals Metabolic Syndrome-Preventive Peptides Derived from Milk Proteins and Their Presence in Cheeses: A Review

2020 ◽  
Vol 10 (8) ◽  
pp. 2772 ◽  
Author(s):  
Anna Iwaniak ◽  
Damir Mogut
Keyword(s):  
Insulin Resistance ◽  
Blood Pressure ◽  
Metabolic Syndrome ◽  
Blood Glucose ◽  
Milk Proteins ◽  
Atherogenic Dyslipidemia ◽  
Converting Enzyme ◽  
The Metabolic Syndrome ◽  
Glucosidase Inhibitors ◽  
Meta Analyses

The metabolic syndrome (MetS) is defined as the occurrence of diet-related diseases such as abdominal obesity, atherogenic dyslipidemia, hyperglycemia (insulin resistance) and hypertension. Milk-derived peptides are well-known agents acting against high blood pressure, blood glucose level, and lipoprotein disproportion. The aim of this review are metabolic syndrome-preventive peptides derived from milk proteins which were identified in cheeses. Special attention was paid to the sequences acting as angiotensin converting enzyme (ACE), dipeptidyl peptidase IV (DDP4), and α-glucosidase inhibitors, as well as antioxidative, hypocholesterolemic, antiobesity, and anti-inflammatory agents. Some results of meta-analyses concerning the consumption of cheese and the risk of MetS diseases were also presented.

scholarly journals High TSH Level within Normal Range Is Associated with Obesity, Dyslipidemia, Hypertension, Inflammation, Hypercoagulability, and the Metabolic Syndrome: A Novel Cardiometabolic Marker

2019 ◽  
Vol 8 (6) ◽  
pp. 817 ◽  
Author(s):  
Yi-Cheng Chang ◽  
Shih-Che Hua ◽  
Chia-Hsuin Chang ◽  
Wei-Yi Kao ◽  
Hsiao-Lin Lee ◽  
...  
Keyword(s):  
Insulin Resistance ◽  
Blood Pressure ◽  
Metabolic Syndrome ◽  
Central Obesity ◽  
Cardiometabolic Risk ◽  
Fasting Glucose ◽  
Reference Group ◽  
Elevated Blood ◽  
Normal Range ◽  
The Metabolic Syndrome

(1) Background: Overt and subclinical hypothyroidism has been associated with increased cardiometabolic risks. Here we further explore whether thyroid function within normal range is associated with cardiometabolic risk factors in a large population-based study. (2) Methods: We screened 24,765 adults participating in health examinations in Taiwan. Participants were grouped according to high-sensitive thyroid-stimulating hormone (hsTSH) level as: <50th percentile (0.47–1.48 mIU/L, the reference group), 50–60th percentile (1.49–1.68 mIU/L), 60–70th percentile (1.69–1.94 mIU/L), 70–80th percentile (1.95–2.3 mIU/L), 80–90th percentile (2.31–2.93 mIU/L), and >90th percentile (>2.93 mIU/L). Cardiometabolic traits of each percentile were compared with the reference group. (3) Results: Elevated hsTSH levels within normal range were dose-dependently associated with increased body mass index, body fat percentage, waist circumferences, blood pressure, hemoglobin A1c (HbA1c), fasting insulin, homeostasis model assessment of insulin resistance (HOMA-IR), high homeostasis model of assessment of beta-cell (HOMA-β), triglycerides, total cholesterols, fibrinogen, and uric acids (p-for-trend <0.001), but not with fasting glucose levels. The association remained significant after adjustment of age, sex, and lifestyle. As compared to the reference group, subjects with the highest hsTSH percentile had significantly increased risk of being overweight (adjusted odds ratio (adjOR): 1.35), increased body fat (adjOR: 1.29), central obesity (adjOR: 1.36), elevated blood pressure (adjOR: 1.26), high HbA1c (adjOR: 1.20), hyperinsulinemia (adjOR: 1.75), increased HOMA-IR (adjOR: 1.45), increased HOMA-β (adjOR: 1.40), hypertriglyceridemia (adjOR: 1.60), hypercholesterolemia (adjOR: 1.25), elevated hsCRP (adjOR: 1.34), increased fibrinogen (adjOR: 1.45), hyperuricemia (adjOR: 1.47), and metabolic syndrome (adjOR: 1.42), but significant risk of low fasting glucose (adjOR: 0.89). Mediation analysis indicates that insulin resistance mediates the majority of the association between thyroid hormone status and the metabolic syndrome. (4) Conclusion: Elevated hsTSH within the normal range is a cardiometabolic risk marker associated with central obesity, insulin resistance, elevated blood pressure, dyslipidemia, hyperuricemia, inflammation, and hypercoagulability.

scholarly journals Electronic Cigarette Use and Metabolic Syndrome Development: A Critical Review

Toxics ◽  
2020 ◽  
Vol 8 (4) ◽  
pp. 105
Author(s):  
Ilona Górna ◽  
Marta Napierala ◽  
Ewa Florek
Keyword(s):  
Insulin Resistance ◽  
Blood Pressure ◽  
Metabolic Syndrome ◽  
Arterial Blood Pressure ◽  
Abdominal Obesity ◽  
Critical Review ◽  
Lifestyle Modifications ◽  
The Metabolic Syndrome ◽  
Arterial Blood ◽  
The Impact

The metabolic syndrome is a combination of several metabolic disorders, such as cardiovascular disease, atherosclerosis, and type 2 diabetes. Lifestyle modifications, including quitting smoking, are recommended to reduce the risk of metabolic syndrome and its associated complications. Not much research has been conducted in the field of e-cigarettes and the risk of metabolic syndrome. Furthermore, taking into account the influence of e-cigarettes vaping on the individual components of metabolic syndrome, i.e, abdominal obesity, insulin resistance, dyslipidemia and elevated arterial blood pressure, the results are also ambiguous. This article is a review and summary of existing reports on the impact of e-cigarettes on the development of metabolic syndrome as well as its individual components. A critical review for English language articles published until 30 June 2020 was made, using a PubMed (including MEDLINE), Cochrane, CINAHL Plus, and Web of Science data. The current research indicated that e-cigarettes use does not affect the development of insulin resistance, but could influence the level of glucose and pre-diabetic state development. The lipid of profile an increase in the TG level was reported, while the influence on the level of concentration of total cholesterol, LDL fraction, and HDL fraction differed. In most cases, e-cigarettes use increased the risk of developing abdominal obesity or higher arterial blood pressure. Further research is required to provide more evidence on this topic.

Biology of metabolic syndrome in a vascular patient

Vascular ◽  
2012 ◽  
Vol 20 (3) ◽  
pp. 156-165 ◽  
Author(s):  
Daynene Vykoukal ◽  
Mark G Davies
Keyword(s):  
Risk Factors ◽  
Insulin Resistance ◽  
Blood Pressure ◽  
Metabolic Syndrome ◽  
Fasting Blood Glucose ◽  
Adverse Impact ◽  
Atherogenic Dyslipidemia ◽  
Elevated Blood ◽  
Vascular Beds ◽  
Vascular Patient

Metabolic syndrome is highly prevalent in vascular patients and has a significant impact on the outcomes of vascular interventions. It comprises of a set of metabolically driven risk factors, including truncal obesity, dyslipidemia, elevated blood pressure and elevated fasting blood glucose. Increased insulin resistance within the context of obesity and hypertension contributes to atherogenic dyslipidemia, hyperglycemia, and prothrombotic and proinflammatory states which lead to the adverse impact of metabolic syndrome on the response to injury and on atherosclerotic disease progression. This review focuses on the complex biology of metabolic syndrome and its relevance to management of vascular patients, including outcomes and implications for the coronary, cerebrovascular and lower-extremity vascular beds.

Effects of pharmacological reversal of hyperuricemia on features of the metabolic syndrome in patients with gouty arthritis

2018 ◽  
Vol 66 (7) ◽  
pp. 1031-1036
Author(s):  
Mariana Marin ◽  
Naim M Maalouf
Keyword(s):  
Insulin Resistance ◽  
Blood Pressure ◽  
Metabolic Syndrome ◽  
Gouty Arthritis ◽  
Oxidase Inhibitor ◽  
Model Assessment ◽  
Urine Ph ◽  
Serum Triglycerides ◽  
Xanthine Oxidase Inhibitor ◽  
The Metabolic Syndrome

Hyperuricemia has been associated in epidemiological studies with the development of obesity, hypertension, insulin resistance and type 2 diabetes. Nevertheless, it remains unclear whether lowering of serum uric acid (UA) alters any of the features of the metabolic syndrome. In this prospective study (ClinicalTrials.gov identifier: NCT01654276), 24 patients with gouty arthritis and hyperuricemia were treated for 6 months with the xanthine oxidase inhibitor febuxostat to lower serum UA to <6 mg/dL. Measurements of 24 hours ambulatory blood pressure (ABP) and serum and urine markers of the metabolic syndrome were measured at baseline and at the end of 6 months of febuxostat. The study population consisted of 18 men and 6 women, 18 of which completed the baseline and 6 months visits. Serum UA decreased significantly from 8.7±1.5 mg/dL at baseline to 4.4±1.1 mg/dL at 6 months (P<0.0001). During that time frame, there was no significant change in body mass index, systolic or diastolic blood pressure measured by 24 hours ABP monitor, serum glucose, insulin or homeostatic model assessment for insulin resistance, serum total and high-density lipoprotein-cholesterol, serum triglycerides or urine pH (P>0.05 for all). There was no correlation between parameters of the metabolic syndrome and the decline in serum UA or serum UA achieved at study end. In conclusion, in patients with gouty arthritis, UA lowering with febuxostat below 6 mg/dL had no significant impact on features of the metabolic syndrome.

scholarly journals Association of Metabolic Syndrome with Sensorineural Hearing Loss

2021 ◽  
Vol 10 (21) ◽  
pp. 4866
Author(s):  
Hwa-Sung Rim ◽  
Myung-Gu Kim ◽  
Dong-Choon Park ◽  
Sung-Soo Kim ◽  
Dae-Woong Kang ◽  
...  
Keyword(s):  
Insulin Resistance ◽  
Blood Pressure ◽  
Metabolic Syndrome ◽  
Hearing Loss ◽  
Sensorineural Hearing Loss ◽  
Sensorineural Hearing ◽  
Health Examination ◽  
Number Of Components ◽  
The Metabolic Syndrome ◽  
Hearing Thresholds

The prevalence of sensorineural hearing loss has increased along with increases in life expectancy and exposure to noisy environments. Metabolic syndrome (MetS) is a cluster of co-occurring conditions that increase the risk of heart disease, stroke and type 2 diabetes, along with other conditions that affect the blood vessels. Components of MetS include insulin resistance, body weight, lipid concentration, blood pressure, and blood glucose concentration, as well as other features of insulin resistance such as microalbuminuria. MetS has become a major public health problem affecting 20–30% of the global population. This study utilized health examination to investigate whether metabolic syndrome was related to hearing loss. Methods: A total of 94,223 people who underwent health check-ups, including hearing tests, from January 2010 to December 2020 were evaluated. Subjects were divided into two groups, with and without metabolic syndrome. In addition, Scopus, Embase, PubMed, and Cochrane libraries were systematically searched, using keywords such as “hearing loss” and “metabolic syndrome”, for studies that evaluated the relationship between the two. Results: Of the 94,223 subjects, 11,414 (12.1%) had metabolic syndrome and 82,809 did not. The mean ages of subjects in the two groups were 46.1 and 43.9 years, respectively. A comparison of hearing thresholds by age in subjects with and without metabolic syndrome showed that the average pure tone hearing thresholds were significantly higher in subjects with metabolic syndrome than in subjects without it in all age groups. (p < 0.001) Rates of hearing loss in subjects with 0, 1, 2, 3, 4, and 5 of the components of metabolic syndrome were 7.9%, 12.1%, 13.8%, 13.8%, 15.5% and 16.3%, respectively, indicating a significant association between the number of components of metabolic syndrome and the rate of hearing loss (p < 0.0001). The odds ratio of hearing loss was significantly higher in subjects with four components of metabolic syndrome: waist circumference, blood pressure, and triglyceride and fasting blood sugar concentrations (p < 0.0001). (4) Conclusions: The number of components of the metabolic syndrome is positively correlated with the rate of sensorineural hearing loss.

Exercise Blood Pressure is associated with Insulin Resistance in subjects with the Metabolic Syndrome.

2008 ◽  
Vol 32 (4) ◽  
pp. 330
Author(s):  
V. Gaudreault ◽  
N. Almeras ◽  
J.P. DesprÉs ◽  
A. Tremblay ◽  
J. Bergeron ◽  
...  
Keyword(s):  
Insulin Resistance ◽  
Blood Pressure ◽  
Metabolic Syndrome ◽  
The Metabolic Syndrome ◽  
Exercise Blood Pressure

scholarly journals Obesity and metabolic syndrome: clinical and therapeutic review

2005 ◽  
Vol 64 (1) ◽  
Author(s):  
Andrea Cuppini ◽  
Paola Matteini
Keyword(s):  
Insulin Resistance ◽  
Blood Pressure ◽  
Metabolic Syndrome ◽  
Cardiovascular Risk ◽  
Multidisciplinary Approach ◽  
Atherogenic Dyslipidemia ◽  
Obese Patients ◽  
Abdominal Adiposity ◽  
The Individual ◽  
Positive Results

The recent ATP III classification defines metabolic syndrome as including ≥3 of the following characteristics: abdominal adiposity, atherogenic dyslipidemia, high blood pressure, and insulin resistance. In these patients the visceral fat may produce inflammatory cytochines that may account for an enhanced cardiovascular risk. The treatment of obese patients is complex and often ineffective: patients may initially reduce weight but subsequently regain or even increase it, according to the socalled “yo-yo syndrome”. Given the difficulties of treatment of patients with incresed BMI, visceral adiposity, or metabolic syndrome, a multidisciplinary approach to these patients may yield more frequent positive results. The different strategies that may be applied, in varying mix targeted to the individual patient, include diet, drugs, educational and psychological support and, in few selected cases, surgery.

Redox-inflammatory synergy in the metabolic syndrome

2013 ◽  
Vol 91 (1) ◽  
pp. 22-30 ◽  
Author(s):  
Sean Bryan ◽  
Boran Baregzay ◽  
Drew Spicer ◽  
Pawan K. Singal ◽  
Neelam Khaper
Keyword(s):  
Oxidative Stress ◽  
Insulin Resistance ◽  
Metabolic Syndrome ◽  
Atherogenic Dyslipidemia ◽  
Disease States ◽  
The Metabolic Syndrome ◽  
Anthropometric Features ◽  
Inflammatory Processes ◽  
Inflammatory Milieu

Metabolic syndrome (MetS) comprises interrelated disease states including obesity, insulin resistance and type 2 diabetes (T2DM), dyslipidemia, and hypertension. Essential to normal physiological function, and yet massively damaging in excess, oxidative stress and inflammation are pivotal common threads among the pathologies of MetS. Increasing evidence indicates that redox and inflammatory dysregulation parallels the syndrome's physiological, biochemical, and anthropometric features, leading many to consider the pro-oxidative, pro-inflammatory milieu an unofficial criterion in itself. Left unchecked, cross-promotion of oxidative stress and inflammation creates a feed-forward cycle that can initiate and advance disease progression. Such redox-inflammatory integration is evident in the pathogenesis of obesity, insulin resistance and T2DM, atherogenic dyslipidemia, and hypertension, and is thus hypothesized to be the “common soil” from which they develop. The present review highlights the synergistic contributions of redox-inflammatory processes to each of the components of the MetS.

scholarly journals LIGHT-ROASTED GREEN COFFEE EXTRACT IMPROVED ADIPONECTIN, INSULIN RESISTANCE, AND METABOLIC PROFILE OF METABOLIC SYNDROME RAT MODEL

2017 ◽  
Vol 10 (9) ◽  
pp. 279 ◽  
Author(s):  
Mifetika Lukitasari ◽  
Dwi Adi Nugroho ◽  
Mohammad Saifur Rohman ◽  
Nur Ida Panca Nugrahini ◽  
Teguh Wahyu Sardjono
Keyword(s):  
Insulin Resistance ◽  
Blood Pressure ◽  
Metabolic Syndrome ◽  
Body Weight ◽  
Blood Glucose ◽  
Metabolic Profile ◽  
Adiponectin Level ◽  
Fasting Blood Glucose ◽  
Enzyme Linked Immunosorbent Assay ◽  
Green Coffee

  Objective: The objective of this study is to investigate the effect of light-roasted green coffee bean extract (GCE) administration for 7 weeks on the improvement of metabolic profile, adiponectin level, homeostatic model assessment insulin resistance (HOMA-IR) index in metabolic syndrome (MS) rat model.Methods: Adult male Sprague-Dawley rats were induced by a combination of high sucrose and high-fat diet for 8 weeks and streptozotocin injection in the 2nd week. The MS was confirmed by NCEP-ATP III criteria. They were divided into six weight-matched groups (n=5), normal control, MS, metformin and simvastatin-treated group (DMS), 100 and 200/body weight (bw) GCE (GCE 100 and GCE 200, respectively). The extracts were given through oral gavage daily for 7 weeks. The effect of GCE on body weight, serum glucose, triglyceride, (TG) and high-density lipoprotein (HDL) level was analyzed by colorimetric method. HOMA-IR index and adiponectin were analyzed by enzyme-linked immunosorbent assay methods.Result: Fasting blood glucose, TG, and systolic blood pressure decreased significantly (p<0.05) in both GCE groups. Moreover, after 7 weeks, those parameters were significantly lower (p<0.05) compared to that of MS group. Only GCE 100 group that showed a significant decrease in HDL level. GCE 100 mg/bw and 200 mg/bw group showed significantly higher adiponectin level compared to that of MS and DMS group. Furthermore, GCE 100, GCE 200, and DMS group showed a significant lower HOMA-IR index compared to that of MS group.Conclusion: 7 weeks GCE administration could decrease fasting blood glucose, profile lipid, blood pressure, and improved adiponectin level and HOMA-IR index.

Sign in / Sign up

Export Citation Format

Share Document